Unlocking disease insights to facilitate drug development: Pharmaceutical industry-academia collaborations in inflammation and immunology

被引：0

作者：

Peeva, Elena ^{[1
]}

Guttman-Yassky, Emma ^{[2
,3
]}

Yamaguchi, Yuji ^{[4
]}

Berman, Brian ^{[5
]}

Oemar, Barry ^{[1
]}

Ramakrishna, Jyoti ^{[1
]}

Fasano, Alessio ^{[6
]}

Evans-Molina, Carmella ^{[7
,8
]}

Chu, Myron ^{[4
]}

Ungar, Benjamin ^{[2
,3
]}

Gulko, Percio S. ^{[9
]}

Padilla, Maria ^{[10
]}

Weiss, Roberta ^{[4
]}

Khosroshahi, Arezou ^{[11
]}

Brunner, Patrick M. ^{[2
,3
]}

Meariman, Marguerite ^{[2
,3
]}

Vincent, Michael S. ^{[1
]}

Dolsten, Mikael ^{[12
]}

机构：

[1] Pfizer, Inflammat & Immunol Res Unit, Cambridge, MA 02139 USA

[2] Icahn Sch Med Mt Sinai, Dept Dermatol, Lab Inflammatory Skin Dis, New York, NY USA

[3] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, New York, NY USA

[4] Pfizer, Inflammat & Immunol Res Unit, Collegeville, PA USA

[5] Univ Miami, Dept Dermatol & Cutaneous Surg, Miami, FL USA

[6] Harvard Med Sch, Massachusetts Gen Hosp Children, Dept Pediat, Div Pediat Gastroenterol & Nutr, Boston, MA USA

[7] Indiana Univ Sch Med, Ctr Diabet & Metab Dis, Dept Pediat, Indianapolis, IN USA

[8] Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Dept Pediat, Indianapolis, IN USA

[9] Icahn Sch Med Mt Sinai, Dept Med, Div Rheumatol, New York, NY USA

[10] Icahn Sch Med Mt Sinai, Dept Med, Div Pulm Crit Care & Sleep Med, New York, NY USA

[11] Emory Univ, Sch Med, Dept Med, Div Rheumatol, Atlanta, GA USA

[12] Pfizer, New York, NY USA

来源：

DRUG DISCOVERY TODAY | 2025年 / 30卷 / 03期

关键词：

academia; autoimmune; collaboration; drug development; immunology; inflammation; pharmaceutical industry; ALOPECIA-AREATA; OPEN INNOVATION; CELIAC-DISEASE; DOUBLE-BLIND; EFFICACY; SAFETY; RITLECITINIB; BREPOCITINIB; ANTIBODIES; MANAGEMENT;

D O I：

10.1016/j.drudis.2025.104317

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Evolving research landscapes warrant updates development strategy. Collaborations between ceutical industry and academic institutions are crucial accelerating drug development, leveraging individual expertise in clinical trial conduct and pathophysi investigations. This review highlights key collab in drug pharmaological orations between Pfizer and academic institutions in inflammation and immunology research, including dermatology, gastroenterology, rheumatology, and autoimmunity. These collaborations harness enhance the development of innovative disease models, large clinical databases, registries, and novel clinical trial designs, and open new avenues in disease management to improve patient outcomes.

引用

页数：13